SOFMEDICA Introduces State-of-the-Art Neuro Care Portfolio

SOFMEDICA is announcing the launch of its groundbreaking NEURO CARE Portfolio with a focus on Brain treatments. This launch marks a significant milestone in the company’s commitment to provide life-saving, precision technologies to patients in New Europe. The technologies presented here address neurodegenerative diseases as a response to the high clinical demand in treating patients who suffer from critical conditions, such as Essential Tremor, Neuropathic pain, Tremor-Dominant Parkinson’s Disease, and brain cancer metastasis.

The new technologies are set to revolutionize the landscape of non-invasive neurological treatments by introducing a novice approach designed to enhance patient outcomes and quality of life. At the heart of this new venture are two pioneering technologies: ZAP-X and Insightec’s Exablate Neuro.

At present, Insightec is revolutionizing the approach to Essential Tremor, Neuropathic pain, and Parkinson’s related tremors, while ZAP is addressing brain cancer metastasis. Looking ahead, the future holds even greater potential for Insightec, as the aim is to extend its applications to address the complexities of Parkinson’s disease, Alzheimer’s, dementia, and the formidable challenge of glioblastoma.

ZAP-X, This dedicated radiosurgery system, is poised to redefine the standards of radiosurgical safety, patient comfort, and convenience. ZAP-X offers a cutting-edge solution that combines precision, speed, and non-invasive treatment methods, ensuring minimal disruption to patients’ lives and a rapid path to recovery. As a painless outpatient procedure with no incision, and often no recovery period, patients typically return to normal activities the same day as treatment. The “vault-free” design eliminates the historical need for prolonged patient isolation in a concrete radiation bunker and the “cobalt-free” feature is improving patient outcome by significantly reducing radiation.

Exablate Neuro by Insightec, This MRI-guided Focused Ultrasound system is designed to treat Essential Tremor, Neuropathic pain, and Tremor-Dominant Parkinson’s Disease. This innovative solution leverages the power of focused ultrasound guided by magnetic resonance imaging, offering a non-invasive and highly precise alternative to traditional intrusive procedures. Exablate Neuro aims to improve the quality of life for patients suffering from these debilitating conditions by providing an effective, safe, and incision-less treatment option. The technology provides excellent clinical results after only one session, allowing personalized treatment for each patient. Future applications for this technology may include the treatment of Parkinson’s disease, Alzheimer and Dementia, as well as glioblastoma, with early research studies in Europe and in the US showing promising results.

Evangelos Kalamakis “Our unwavering commitment to patients suffering from neurodegenerative conditions is reflected in providing innovative solutions tailored to their needs. In Romania, due to the lack of advanced facilities and technologies, patients with Parkinson’s disease, characterized by specific tremors, often receive their diagnosis at advanced stages when the symptoms are debilitating. Through these non-invasive approaches we will significantly contribute to improving the quality of life for patients with neurological conditions.”  Evangelos Kalamakis, Managing Director.

SOFMEDICA has been at the forefront of the battle against life-threatening conditions, from various types of cancers to cardiovascular diseases, pioneering state-of-the-art technologies that have changed countless lives across New Europe. The company’s commitment extends even further with the introduction of the innovative NEURO CARE technologies, advancing the treatment landscape for neurodegenerative conditions that impact the individuals who suffer from them and their families.

SOFMEDICA – Life-Saving Innovation is a member of SOFMEDICA Group, an education-oriented Group of Companies focused on healthcare, operating in Europe (Romania, Greece, Bulgaria, Cyprus, Hungary, Croatia) since 1994 aiming at the creation of sustainable, improved clinical outcomes for patients in European countries SOFMEDICA deploys its activities through a team of 160 mission-oriented professionals and is expected to report an annual turnover of approximately €60 million in 2023.  Neurocare technologies represent the latest addition to SOFMEDICA’s portfolio.